Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6419MR)

This product GTTS-WQ6419MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6419MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ706MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ4197MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ13562MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ3038MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ5980MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ9468MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ6400MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ12919MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW